Motor cortex inhibition as a fibromyalgia biomarker
Brain Network and Modulation · 2022-04 · 1 (2) · 88-101
DOI: 10.4103/2773-2398.348254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Network and Modulation, 2022-04. Verfasst von Kevin Pacheco-Barrios und 10 weiteren Autor:innen. Beteiligte Einrichtung: Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medic…. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCCIH NIH HHS.
Abstract (Originalsprache)
Fibromyalgia (FM) is a common and refractory chronic pain condition with multiple clinical phenotypes. The current diagnosis is based on a syndrome identification which can be subjective and lead to under or over-diagnosis. Therefore, there is a need for objective biomarkers for diagnosis, phenotyping, and prognosis (treatment response and follow-up) in fibromyalgia. Potential biomarkers are measures of cortical excitability indexed by transcranial magnetic stimulation (TMS). However, no systematic analysis of current evidence has been performed to assess the role of TMS metrics as a fibromyalgia biomarker. Therefore, this study aims to evaluate evidence on corticospinal and intracortical motor excitability in fibromyalgia subjects and to assess the prognostic role of TMS metrics as response biomarkers in FM. We conducted systematic searches on PubMed/Medline, Embase, and Cochrane Central databases for observational studies and randomized controlled trials on fibromyalgia subjects that used TMS as an assessment. Three reviewers independently selected and extracted the data. Then, a random-effects model meta-analysis was performed to compare fibromyalgia and healthy controls in observational studies. Also, to compare active versus sham treatments, in randomized controlled trials. Correlations between changes in TMS metrics and clinical improvement were explored. The quality and evidence certainty were assessed following standardized approaches. We included 15 studies (474 FM subjects and 222 controls). The main findings were: (1) fibromyalgia subjects present less intracortical inhibition (mean difference [MD, including] = –0.40, 95% confidence interval [CI] –0.69 to –0.11) and higher resting motor thresholds (MD = 6.90 μV, 95% CI 4.16 to 9.63 μV) when compared to controls; (2) interventions such as exercise, pregabalin, and non-invasive brain stimulation increased intracortical inhibition (MD = 0.19, 95% CI 0.10 to 0.29) and cortical silent period (MD = 14.92 ms, 95% CI 4.86 to 24.98 ms), when compared to placebo or sham stimulation; (3) changes on intracortical excitability are correlated with clinical improvements – higher inhibition moderately correlates with less pain, depression, and pain catastrophizing; lower facilitation moderately correlates with less fatigue. Measures of intracortical inhibition and facilitation indexed by TMS are potential diagnostic and treatment response biomarkers for fibromyalgia subjects. The disruption in the intracortical inhibitory system in fibromyalgia also provides additional evidence that fibromyalgia has some neurophysiological characteristics of neuropathic pain. Treatments inducing an engagement of sensorimotor systems (e.g., exercise, motor imagery, and non-invasive brain stimulation) could restore the cortical inhibitory tonus in FM and induce clinical improvement.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
- Universidad San Ignacio de Loyola, Vicerrectorado de Investigación, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Lima, Peru.
- Georg-August-University Goettingen, International Max Planck Research School for Neurosciences, Goettingen, Germany.
Förderung
- NCCIH NIH HHS
Zitieren
APA
Pacheco-Barrios, K., Lima, D., Pimenta, D., Slawka, E., Navarro-Flores, A., Parente, J., Rebello-Sanchez, I., Cardenas-Rojas, A., Gonzalez-Mego, P., Castelo-Branco, L., & Fregni, F. (2022). Motor cortex inhibition as a fibromyalgia biomarker. Brain Network and Modulation, 1(2), 88-101. https://doi.org/10.4103/2773-2398.348254
Vancouver
Pacheco-Barrios K, Lima D, Pimenta D, Slawka E, Navarro-Flores A, Parente J, et al. Motor cortex inhibition as a fibromyalgia biomarker. Brain Network and Modulation. 2022;1(2):88-101. doi:10.4103/2773-2398.348254
BibTeX
@article{PachecoBarrios2022,
author = {Pacheco-Barrios, Kevin and Lima, Daniel and Pimenta, Danielle and Slawka, Eric and Navarro-Flores, Alba and Parente, Joao and Rebello-Sanchez, Ingrid and Cardenas-Rojas, Alejandra and Gonzalez-Mego, Paola and Castelo-Branco, Luis and Fregni, Felipe},
title = {Motor cortex inhibition as a fibromyalgia biomarker},
journal = {Brain Network and Modulation},
year = {2022},
volume = {1},
number = {2},
pages = {88--101},
doi = {10.4103/2773-2398.348254}
}
EUVIMED